Head-to-head evidence
Elacestrant vs tamoxifen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc.
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
tamoxifen
Marketed by Mayne Pharma
NCT00066690 · Phase 3 · completed
The trial was large and randomized, with tamoxifen as an active comparator, but it was open-label rather than blinded. Its hard primary endpoint, five-year disease-free survival, produced mixed results: exemestane plus ovarian suppression was superior to tamoxifen alone, whereas tamoxifen plus ovarian suppression was not statistically significant compared with tamoxifen alone.
Next expected readout: October 2026 · NCT03707340 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · tamoxifen's landscape